NCT04562428View on ClinicalTrials.gov

The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

May 30, 2023

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Xiang Sha Liu Jun Zi Decoction dry powder

the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei

DRUG

XSLJZ Placebo

XSLJZ Placebo

Trial Locations (1)

407

China Medical University hospital, Taichung

All Listed Sponsors
lead

China Medical University Hospital

OTHER

NCT04562428 - The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial | Biotech Hunter | Biotech Hunter